Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ. Radich JP, et al. Among authors: kantarjian hm. Haematologica. 2023 Jun 1;108(6):1567-1578. doi: 10.3324/haematol.2022.281878. Haematologica. 2023. PMID: 36727397 Free PMC article.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Nguyen D, et al. Among authors: kantarjian hm. Cancer. 2023 Jun 15;129(12):1856-1865. doi: 10.1002/cncr.34728. Epub 2023 Mar 9. Cancer. 2023. PMID: 36892949 Free article.
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. Boddu PC, et al. Among authors: kantarjian hm. Cancer. 2023 Feb 15;129(4):580-589. doi: 10.1002/cncr.34570. Epub 2022 Nov 29. Cancer. 2023. PMID: 36448227 Free article. Clinical Trial.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36402146 Clinical Trial.
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Almanza-Huante E, et al. Among authors: kantarjian hm. Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23. Br J Haematol. 2023. PMID: 36951293 No abstract available.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Benjamin R, et al. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. Lancet. 2020. PMID: 33308471 Clinical Trial.
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation.
Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM. Senapati J, et al. Among authors: kantarjian hm. Am J Hematol. 2025 Feb;100(2):249-259. doi: 10.1002/ajh.27561. Epub 2024 Dec 24. Am J Hematol. 2025. PMID: 39718824
1,047 results